EBITDA Margin % is calculated as EBITDA divided by its Revenue. vTv Therapeutics's EBITDA for the
three
months ended in Mar. 2026 was $23.26 Mil. vTv Therapeutics's Revenue for the
three
months ended in Mar. 2026 was $36.84 Mil. Therefore, vTv Therapeutics's EBITDA margin for the quarter that ended in Mar. 2026 was 63.15%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
vTv Therapeutics EBITDA Margin % Related Terms
vTv Therapeutics EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for vTv Therapeutics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VTVT vs CRDF, GUTS, ACOG: EBITDA Margin % Comparison
For the Biotechnology subindustry, vTv Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
vTv Therapeutics EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, vTv Therapeutics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where vTv Therapeutics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
vTv Therapeutics (VTVT) has a EBITDA Margin % of 63.15% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on vTv Therapeutics and its competitors. According to the industry distribution chart, vTv Therapeutics ranks #330 out of 944 companies in the Biotechnology industry, placing it in the top 35%.
Is vTv Therapeutics' EBITDA Margin % too high?
vTv Therapeutics' current EBITDA Margin % is 63.15%. Based on the distribution chart, vTv Therapeutics ranks #330 out of 944 companies in the Biotechnology industry, which is above the industry midpoint. Overall, vTv Therapeutics has a GF Score™ of 35/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does vTv Therapeutics' EBITDA Margin % compare to CRDF and GUTS?
According to the Biotechnology industry distribution chart, vTv Therapeutics ranks #330 out of 944 companies for EBITDA Margin %. This puts vTv Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on vTv Therapeutics and its competitors. vTv Therapeutics's current EBITDA Margin % is 63.15%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is vTv Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, vTv Therapeutics (VTVT) is currently considered Significantly Undervalued. The stock's GF Value™ is $7,827.31, compared to a current price of $37.14 — trading 99.5% below its estimated fair value. The current EBITDA Margin % is 63.15%. vTv Therapeutics' overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For vTv Therapeutics (VTVT), the current EBITDA Margin % is 63.15% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is vTv Therapeutics (VTVT) Overvalued in 2026?
Based on GuruFocus' analysis, vTv Therapeutics stock appears to be undervalued.
The current stock price of $37.14 is trading 99.5% below its estimated GF Value™ of $7,827.31.
GuruFocus considers vTv Therapeutics to be Significantly Undervalued.
Key valuation signals for VTVT:
EBITDA Margin %: 63.15%
GF Value™: $7,827.31 vs. price of $37.14 (99.5% below fair value)
No single metric tells the full story. See the VTVT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.
35GF Score
Get the complete analysis for VTVT
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VTVT has been successfully added to your 
